

ABSENCE OF EXCESS BODY FATNESS

VOLUME 16

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met in Lyon, 5–12 April 2016

LYON, FRANCE - 2018

IARC HANDBOOKS OF
CANCER PREVENTION

CONTENTS

| | |
|---|----|
| NOTE TO THE READER | 1 |
| LIST OF PARTICIPANTS | 3 |
| WORKING PROCEDURES | 7 |
| A. GENERAL PRINCIPLES AND PROCEDURES | 7 |
| 1. Background | 7 |
| 2. Objective and scope | 7 |
| 3. Selection of interventions for review | 8 |
| 4. Data for the <i>IARC Handbooks</i> | 8 |
| 5. Meeting participants | 9 |
| B. SCIENTIFIC REVIEW AND EVALUATION | 10 |
| 1. Characteristics and occurrence of the intervention..... | 11 |
| 2. Studies of cancer prevention in humans..... | 11 |
| 3. Studies of cancer prevention in experimental animals | 13 |
| 4. Mechanistic and other relevant data | 15 |
| 5. Summary of data | 17 |
| 6. Evaluation and rationale | 17 |
| References | 20 |
| GENERAL REMARKS | 21 |
| LIST OF ABBREVIATIONS | 25 |
| 1. BODY FATNESS | 29 |
| 1.1 Background and definitions..... | 29 |
| 1.1.1 Scientific definitions of obesity..... | 29 |
| 1.1.2 Cultural definitions of obesity..... | 29 |
| 1.1.3 Body fatness as a public health problem | 30 |
| 1.2 Prevalence and trends | 30 |
| 1.2.1 Prevalence and trends in adults..... | 30 |
| 1.2.2 Prevalence and trends in children and adolescents..... | 31 |
| 1.2.3 Prevalence by age and sex | 34 |
| 1.2.4 Prevalence by ethnicity | 35 |
| 1.2.5 Prevalence by social class and education..... | 36 |

| | | |
|-----------|---|-----------|
| 1.3 | Risk factors..... | 37 |
| 1.3.1 | Regulation of hunger and satiety..... | 37 |
| 1.3.2 | Weight gain throughout the life-course..... | 38 |
| 1.3.3 | Excessive energy intake..... | 40 |
| 1.3.4 | Endocrine disruptors..... | 42 |
| 1.3.5 | Physical activity and sedentary behaviour..... | 44 |
| 1.3.6 | Built environment..... | 45 |
| 1.3.7 | Social determinants..... | 47 |
| 1.3.8 | Microbiota and gastrointestinal environment..... | 48 |
| 1.3.9 | Genetic and epigenetic determinants of body fatness..... | 49 |
| 1.4 | Assessment of anthropometric measures and body composition..... | 50 |
| 1.4.1 | Weight and height..... | 50 |
| 1.4.2 | Indexes of adiposity..... | 51 |
| 1.4.3 | Other measures of adiposity or body composition..... | 53 |
| 1.4.4 | Change in weight..... | 55 |
| 1.4.5 | Assessment of paediatric adiposity..... | 56 |
| | References..... | 56 |
| 2. | CANCER-PREVENTIVE EFFECTS IN HUMANS..... | 71 |
| 2.1 | Methodological considerations..... | 71 |
| 2.1.1 | Bias..... | 71 |
| 2.1.2 | Confounding..... | 72 |
| 2.1.3 | Reverse causation..... | 72 |
| 2.1.4 | Mendelian randomization..... | 73 |
| | References..... | 73 |
| 2.2 | Cancer-preventive effects by organ site..... | 74 |
| 2.2.1 | Cancer of the colorectum..... | 74 |
| | References..... | 109 |
| 2.2.2 | Cancer of the oesophagus..... | 113 |
| | References..... | 132 |
| 2.2.3 | Cancer of the stomach..... | 134 |
| | References..... | 161 |
| 2.2.4 | Cancer of the liver (hepatocellular carcinoma)..... | 164 |
| | References..... | 180 |
| 2.2.5 | Cancer of the gall bladder..... | 182 |
| | References..... | 192 |
| 2.2.6 | Cancers of the biliary tract..... | 194 |
| | References..... | 195 |
| 2.2.7 | Cancer of the pancreas..... | 196 |
| | References..... | 227 |
| 2.2.8 | Cancer of the lung..... | 231 |
| | References..... | 233 |
| 2.2.9 | Cancer of the breast in women..... | 235 |
| | References..... | 283 |
| 2.2.10 | Cancer of the breast in men..... | 290 |
| | Reference..... | 290 |

| | |
|--|------------|
| 2.2.11 Cancer of the endometrium | 291 |
| References | 307 |
| 2.2.12 Cancer of the cervix | 311 |
| References | 311 |
| 2.2.13 Cancer of the ovary | 313 |
| References | 333 |
| 2.2.14 Cancer of the prostate | 336 |
| References | 375 |
| 2.2.15 Cancer of the testis | 380 |
| References | 381 |
| 2.2.16 Cancer of the kidney (renal cell carcinoma) | 382 |
| References | 396 |
| 2.2.17 Cancer of the urinary bladder | 398 |
| References | 399 |
| 2.2.18 Primary tumours of the brain and central nervous system | 401 |
| References | 410 |
| 2.2.19 Cancer of the thyroid | 411 |
| References | 420 |
| 2.2.20 Haematopoietic malignancies of lymphoid origin | 422 |
| References | 450 |
| 2.2.21 Other haematopoietic malignancies | 453 |
| References | 454 |
| 2.2.22 Cancers of the head and neck | 456 |
| References | 459 |
| 2.2.23 Malignant melanoma | 461 |
| References | 462 |
| 2.3. Excess body fatness in early life and subsequent cancer risk | 463 |
| 2.3.1 Weight and height measured in childhood | 463 |
| 2.3.2 Body shape in early adulthood determined by recall | 464 |
| 2.3.3 Trajectories of body shape determined from early life | 465 |
| References | 475 |
| 2.4 Excess body fatness in cancer survivors | 477 |
| 2.4.1 Studies of weight at diagnosis and cancer outcomes | 477 |
| 2.4.2 Studies of weight change after cancer diagnosis and cancer outcomes | 478 |
| 2.4.3 Intervention trials of weight-loss intervention and dietary modification | 478 |
| References | 479 |
| 2.5 Sustained weight loss and cancer risk: illustrative examples | 481 |
| 2.5.1 Studies of weight loss and cancer risk | 481 |
| 2.5.2 Studies of bariatric surgery and cancer risk | 481 |
| References | 485 |
| 3. CANCER-PREVENTIVE EFFECTS IN EXPERIMENTAL ANIMALS | 487 |
| 3.1 Methodological considerations | 487 |
| 3.1.1 Definition of dietary/calorie restriction | 487 |
| 3.1.2 Design issues in studies of dietary restriction | 487 |
| 3.2 Overview of the effects of excess body weight | 489 |

| | | |
|-----------|--|------------|
| 3.2.1 | Obesity models | 489 |
| 3.2.2 | Cancer of the mammary gland | 490 |
| 3.2.3 | Cancer of the colon | 493 |
| 3.2.4 | Cancer of the liver | 494 |
| 3.2.5 | Cancer of the prostate | 495 |
| 3.2.6 | Cancer of the skin (melanoma) | 497 |
| 3.2.7 | Cancer of the pancreas | 498 |
| 3.2.8 | Cancer of the endometrium of the uterus | 499 |
| 3.2.9 | Leukaemia | 499 |
| 3.3 | Preventive effects of dietary/calorie restriction | 500 |
| 3.3.1 | Cancer of the mammary gland | 500 |
| 3.3.2 | Cancer of the colon | 514 |
| 3.3.3 | Cancer of the liver | 518 |
| 3.3.4 | Cancer of the pancreas | 522 |
| 3.3.5 | Cancer of the skin and subcutaneous tissue | 526 |
| 3.3.6 | Cancer of the pituitary gland | 531 |
| 3.3.7 | Cancer of the prostate | 537 |
| 3.3.8 | Cancers of the haematopoietic system | 537 |
| | References | 545 |
| 4. | MECHANISTIC AND OTHER RELEVANT DATA | 553 |
| 4.1 | Introduction | 553 |
| 4.2 | Intracellular factors | 554 |
| 4.2.1 | Cell proliferation, apoptosis, and angiogenesis | 554 |
| 4.2.2 | The mTOR network and other energy-sensor networks | 557 |
| 4.2.3 | Epigenetics, oxidative stress, DNA repair, and telomeres | 559 |
| 4.3 | Receptor-mediated effects | 564 |
| 4.3.1 | Sex hormones | 564 |
| 4.3.2 | Insulin resistance | 567 |
| 4.3.3 | Insulin-like growth factors | 570 |
| 4.3.4 | Chronic inflammation | 571 |
| 4.3.5 | Vitamin D | 577 |
| 4.3.6 | Other factors | 579 |
| | References | 611 |
| 5. | SUMMARY OF DATA | 633 |
| 5.1 | Exposure data | 633 |
| 5.2 | Cancer-preventive effects in humans | 634 |
| 5.2.1 | Cancer of the colorectum | 634 |
| 5.2.2 | Cancer of the oesophagus | 635 |
| 5.2.3 | Cancer of the stomach | 635 |
| 5.2.4 | Cancer of the liver (hepatocellular carcinoma) | 635 |
| 5.2.5 | Cancer of the gall bladder | 635 |
| 5.2.6 | Cancers of the biliary tract | 636 |
| 5.2.7 | Cancer of the pancreas | 636 |
| 5.2.8 | Cancer of the lung | 636 |

| | | |
|----------------------|--|------------|
| 5.2.9 | Cancer of the breast in women | 636 |
| 5.2.10 | Cancer of the breast in men | 636 |
| 5.2.11 | Cancer of the endometrium | 636 |
| 5.2.12 | Cancer of the cervix | 637 |
| 5.2.13 | Cancer of the ovary | 637 |
| 5.2.14 | Cancer of the prostate | 637 |
| 5.2.15 | Cancer of the testis | 637 |
| 5.2.16 | Cancer of the kidney (renal cell carcinoma) | 637 |
| 5.2.17 | Cancer of the urinary bladder | 637 |
| 5.2.18 | Primary tumours of the brain and central nervous system | 638 |
| 5.2.19 | Cancer of the thyroid | 638 |
| 5.2.20 | Tumours of the haematopoietic system | 638 |
| 5.2.21 | Cancers of the head and neck | 638 |
| 5.2.22 | Malignant melanoma | 639 |
| 5.2.23 | Excess body fatness in early life and subsequent cancer risk | 639 |
| 5.2.24 | Excess body fatness in cancer survivors | 639 |
| 5.2.25 | Sustained weight loss and cancer risk | 639 |
| 5.3 | Cancer-preventive effects in experimental animals | 639 |
| 5.3.1 | Excess body weight | 639 |
| 5.3.2 | Dietary/calorie restriction | 640 |
| 5.4 | Mechanistic and other relevant data | 643 |
| 5.4.1 | Sex hormone metabolism | 643 |
| 5.4.2 | Inflammation | 643 |
| 5.4.3 | Insulin and insulin-like growth factor | 644 |
| 5.4.4 | Epigenetic alterations | 644 |
| 5.4.5 | Oxidative stress | 644 |
| 5.4.6 | DNA repair | 644 |
| 5.4.7 | Telomeres | 644 |
| 5.4.8 | Other mechanisms | 644 |
| 6. EVALUATION | | 645 |
| 6.1 | Cancer-preventive effects in humans | 645 |
| 6.2 | Cancer-preventive effects in experimental animals | 645 |
| 6.3 | Mechanistic and other relevant data | 645 |
| 6.4 | Overall evaluation | 645 |